 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Vertex Pharmaceuticals Incorporated
 |
Vertex Pharmaceuticals Incorporated |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Vertex posts Q2 loss of 16 cents Jul 26 2001 02:06 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Vertex Pharmaceuticals represents the convergence of drug discovery technologies. The firm uses a multidisciplinary approach to discover the structure of malfunctioning molecules associated with a disease and to design compounds that alter those molecules' functions. The tools used in this process -- biophysics, chemistry, and computer-based modeling -- eliminate the traditional trial-and-error approach to drug development. Vertex targets viruses (its Agenerase has been approved for HIV treatment in the US and is marketed by GlaxoSmithKline), cancer, and autoimmune, inflammatory, and neurological diseases. The company has collaborative agreements with Novartis, Eli Lilly, Aventis, and Schering AG, among others.
COMPETITION |
 |
Abbott Laboratories (ABT)
Merck & Co., Inc. (MRK)
Shire BioChem Inc. (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 78.10
1-Yr. Sales Growth: 26.8%
Employees: 455
Revenue per employee: $171,648.35
KEY PEOPLE |
 |
Joshua S. Boger
CEO
Thomas G. Auchincloss
CFO
CONTACT INFO |
 |
130 Waverly St.
Cambridge, MA 02139
US
Phone: 617-577-6000
Fax: 617-577-6680
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |